Bio-Rad Laboratories, Inc. (BIO-B) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Multiple concerning factors at $275.00: Overbought (RSI 100); Weak growth.
Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025 net sales) and clinical diagnostics (60%), operating directly in 36+ countries. ~60% of sales are international with Europe as the largest region; the company... Read more
Sell if holding. Multiple concerning factors at $275.00: Overbought (RSI 100); Weak growth. Chart setup: Death cross but MACD improving, RSI 100. Score 5.3/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02LOWStockholders approved the Amended 2017 Incentive Award Plan at the April 21, 2026 annual meeting, adding 335,000 shares and extending expiration to March 18, 2036. Routine compensatory arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $275.00: Overbought (RSI 100); Weak growth. Chart setup: Death cross but MACD improving, RSI 100. Prior stop was $296.25. Score 5.3/10, moderate confidence.
Take-profit target: $344.37 (+15.0% upside). Prior stop was $296.25. Stop-loss: $296.25.
Weak growth; Overbought (RSI 100).
Bio-Rad Laboratories, Inc. trades at a P/E of 10.8 (forward N/A). TrendMatrix value score: 6.0/10. Verdict: Sell.
10 analysts cover BIO-B with a consensus score of 3.8/5.
What does Bio-Rad Laboratories, Inc. do?Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025...
Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025 net sales) and clinical diagnostics (60%), operating directly in 36+ countries. ~60% of sales are international with Europe as the largest region; the company also holds a $5.7B fair-value equity stake in Sartorius AG (38% of ordinary shares).